登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Nucleocapsid protein >NUN-C52Hv

SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron)

该产品是BA.3 Nucleocapsid蛋白的一种低频突变,如需常规版本请查看NUN-C52Hu。

分子别名(Synonym)

Nucleocapsid protein,NP,Protein N

表达区间及表达系统(Source)

SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron) (NUN-C52Hv) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 419 (Accession # QHO62115.1 (P13L, GER 30-32del, S33V, R203K, G204R, S413R)). The mutations (P13L, GER 30-32del, S33V, R203K, G204R, S413R) were identified in the SARS-CoV-2 Omicron variant (Pango lineage: BA.3; GISAID clade: GRA; Nextstrain clade: 21M).

Predicted N-terminus: Met 1

Request for sequence

蛋白结构(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 47.1 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Nucleocapsid protein SDS-PAGE

SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Nucleocapsid protein ELISA

Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron) (Cat. No. NUN-C52Hv) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (Cat. No. NUN-CH15) with a linear range of 0.5-2 ng/mL (QC tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.

 

前沿进展

Electroconvulsive Therapy in Cochlear Implant Users
Crotty, Alshehri, Gendre et al
J ECT (2025)
Abstract: Cochlear implant manufacturers currently contraindicate the use of electroconvulsive therapy (ECT) in CI users, citing theoretical evidence of potential harm to the patient or the implant despite a lack of clinical data. We report two uncomplicated cases of ECT in CI users, including the first reported case of bilateral ECT in a patient with bilateral CIs.The first case involves a 66-year-old visually impaired male with bilateral CIs. He suffered from major depressive disorder complicated by refusal of oral intake despite maximal pharmacological therapy. He underwent 9 consecutive cycles of bilateral ECT, after which his psychiatric condition improved. Cochlear implant function remained unchanged following the procedure. The second case involved a 65-year-old female with a left-sided CI and a history of recurrent depressive disorder. Her condition deteriorated with the onset of auditory hallucinations and increased suicidality. She underwent 8 consecutive cycles of unilateral ECT with right-sided electrode placement. Her psychiatric condition improved, and there was no change in CI impedance following the procedure.We report 2 successful cases of ECT in CI users, including the first reported case of bilateral ECT in a patient with bilateral cochlear implants. Further investigation into the safety of ECT in CI users is warranted to ensure that this crucial treatment modality remains available to this vulnerable patient cohort.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Design of Porous 3D Interdigitated Current Collectors and Hybrid Microcathodes for Zn-Ion Microcapacitors
Fan, Naresh, Zhu et al
ACS Nano (2025)
Abstract: Zinc-ion microcapacitors (ZIMCs) have gained considerable attention for their intrinsic charge storage mechanisms, combining a battery-type anode with a capacitor-type cathode. However, their development is constrained by challenges related to electrode material selection and microscale device design, especially given the limited footprint of such devices. Despite their potential, exploration of smart electrode processing and hybrid materials for on-chip ZIMCs remains limited. In this work, we introduce 3D gold interdigitated electrodes (3D Au IDEs) as highly porous current collectors, loaded with zinc (Zn) as the anode and hybrid activated carbon coated with PEDOT (AC-PEDOT) as the cathode, using an advanced microplotter fabrication technique. Compared with planar Zn//AC ZIMCs, where Zn and AC materials are loaded onto planar Au IDEs, the 3D Au Zn//AC-PEDOT ZIMCs demonstrate significantly enhanced performance. This is attributed to the critical role of IDEs in increasing the charge storage capacity, improving long-term cycling stability, and boosting capacitive-controlled charge storage contributions. The 3D Au Zn//AC-PEDOT ZIMCs achieve an areal capacity of 1.3 μAh/cm2, peak areal energy of 1.11 μWh/cm2, and peak areal power of 640 μW/cm2, surpassing most reported microsupercapacitors. This study highlights how optimized collectors and hybrid electrodes enhance microdevice charge storage while maximizing performance within a constrained footprint.
Protocol for evaluating neuronal activity and neurotransmitter release following amyloid-beta oligomer injections into the rat hippocampus
Hervé, Bonenfant, Amyot et al
STAR Protoc (2025) 6 (2), 103712
Abstract: In Alzheimer's disease, there is an imbalance in neurotransmitter release and altered neuronal activation. Here, we present a protocol approach to analyze neuronal activity by combining local field potential (LFP) recording with microdialysis within the same animal. We describe steps for measuring glutamate and GABA levels following hippocampal amyloid-beta oligomer (Aβo) injections in rats. We then detail procedures for assembling the electrode and cannula, surgical implantation and simultaneous in vivo LFP recording, interstitial fluid collection, and Aβo injections.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Can Difluoroethylene Carbonate Replace Fluoroethylene Carbonate for High-Performance Lithium-Ion Cells at High Voltage?
Guan, Ouyang, Wan et al
ACS Appl Mater Interfaces (2025)
Abstract: To date, optimizing electrolytes has become a promising approach to enable high-voltage, high-performance lithium-ion cells. Herein, a study is performed to evaluate the potential of difluoroethylene carbonate (DFEC) to replace fluoroethylene carbonate (FEC) and deliver comparable or even superior performance at high voltage. It is unveiled that moderately increasing lithium salt inside the DFEC-based electrolyte enhances the high-voltage performance of cells, with the DFEC-based electrolyte outperforming the FEC-based counterpart. Moreover, the DFEC-based electrolyte also fits the LiFePO4 system where a high performance is illustrated when charged to 3.8 and 4.0 V. As a result of the low binding energy between DFEC and Li+, an anion-rich solvation structure is formed by the DFEC-based electrolyte, facilitating Li+ intercalation/deintercalation and forming inorganic-rich passivation layers. In addition, the cell's electrode-electrolyte interface is well-protected due to the superior film property of DFEC, where a thin, smooth, and robust passivation layer is generated that efficiently prevents the electrode and electrolyte from side reactions under high voltage. Furthermore, the DFEC-based electrolyte and the cells containing it also demonstrate superior safety properties when exposed to typical safety testing. Hence, DFEC is shown to be a viable alternative to FEC for enabling sound-performance lithium-ion cells at a high voltage.
Showing 1-4 of 310892 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Nucleocapsid protein靶点信息
英文全称:Nucleocapsid proteins
中文全称:核壳蛋白
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:1详情
最高研发阶段:临床一期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定